CLNN
Clene Inc.
Biotechnology
Market Cap$74M
5Y Perf.-96.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CLNN vs NRXP
Revenue, margins, valuation, and 5-year total return — side by side.
NRXP
NRx Pharmaceuticals, Inc.
Biotechnology
Market Cap$85M
5Y Perf.-97.2%
CLNN vs NRXP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CLNN | NRXP |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $74M | $85M |
| Revenue (TTM) | $200K | $242K |
| Net Income (TTM) | $-26M | $-38M |
| Gross Margin | 78.5% | 59.5% |
| Operating Margin | -115.4% | -63.0% |
| Total Debt | $22M | $631K |
| Cash & Equiv. | $5M | $8M |
CLNN vs NRXP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CLNN
NRXP
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Clene Inc. (CLNN) | 100 | 3.5 | -96.5% |
| NRx Pharmaceuticals… (NRXP) | 100 | 2.8 | -97.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CLNN vs NRXP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CLNN leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. NRx Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
CLNN
Clene Inc.
The Growth Play
CLNN carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth -41.5%, EPS growth 53.3%, 3Y rev CAGR -24.9%
- -96.2% 10Y total return vs NRXP's -96.8%
- -130.9% margin vs NRXP's -157.3%
Best for: growth exposure and long-term compounding
NRXP
NRx Pharmaceuticals, Inc.
The Income Pick
NRXP is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.91
- Lower volatility, beta 1.91, current ratio 0.31x
- Beta 1.91, current ratio 0.31x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NRXP | 101.1% revenue growth vs CLNN's -41.5% |
| Quality / Margins | CLNN | -130.9% margin vs NRXP's -157.3% |
| Stability / Safety | NRXP | Beta 1.91 vs CLNN's 1.97 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CLNN | +189.8% vs NRXP's +55.3% |
| Efficiency (ROA) | CLNN | -119.1% ROA vs NRXP's -489.9% |
CLNN vs NRXP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
CLNN vs NRXP — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCLNNLAGGINGNRXP
NRXPNRx Pharmaceuticals, …
2leads
CLNNClene Inc.
2leads
6 Total Categories
CATEGORYLEADERvs NRXPMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CLNN3/5
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
NRXP3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
CLNN4/6
Risk & VolatilityBeta, volatility, and downside exposure
NRXP2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CLNN leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
NRXP and CLNN operate at a comparable scale, with $242,000 and $200,000 in trailing revenue. CLNN is the more profitable business, keeping -130.9% of every revenue dollar as net income compared to NRXP's -157.3%.
| Metric | CLNNClene Inc. | NRXPNRx Pharmaceutica… |
|---|---|---|
| RevenueTrailing 12 months | $200,000 | $242,000 |
| EBITDAEarnings before interest/tax | -$22M | -$31M |
| Net IncomeAfter-tax profit | -$26M | -$38M |
| Free Cash FlowCash after capex | -$19M | -$12M |
| Gross MarginGross profit ÷ Revenue | +78.5% | +59.5% |
| Operating MarginEBIT ÷ Revenue | -115.4% | -63.0% |
| Net MarginNet income ÷ Revenue | -130.9% | -157.3% |
| FCF MarginFCF ÷ Revenue | -92.9% | -49.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -15.4% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +52.3% | -80.0% |
CLNN leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
Evenly matched — CLNN and NRXP each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | CLNNClene Inc. | NRXPNRx Pharmaceutica… |
|---|---|---|
| Market CapShares × price | $74M | $85M |
| Enterprise ValueMkt cap + debt − cash | $90M | $78M |
| Trailing P/EPrice ÷ TTM EPS | -2.79x | -2.28x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 369.50x | 69.15x |
| Price / BookPrice ÷ Book value/share | — | — |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — CLNN and NRXP each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
NRXP leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), NRXP scores 5/9 vs CLNN's 1/9, reflecting solid financial health.
| Metric | CLNNClene Inc. | NRXPNRx Pharmaceutica… |
|---|---|---|
| ROE (TTM)Return on equity | — | — |
| ROA (TTM)Return on assets | -119.1% | -4.9% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -189.2% | — |
| Piotroski ScoreFundamental quality 0–9 | 1 | 5 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | $16M | -$7M |
| Cash & Equiv.Liquid assets | $5M | $8M |
| Total DebtShort + long-term debt | $22M | $631,000 |
| Interest CoverageEBIT ÷ Interest expense | -8.61x | -24.18x |
NRXP leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
CLNN leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CLNN five years ago would be worth $402 today (with dividends reinvested), compared to $92 for NRXP. Over the past 12 months, CLNN leads with a +189.8% total return vs NRXP's +55.3%. The 3-year compound annual growth rate (CAGR) favors NRXP at -21.0% vs CLNN's -26.6% — a key indicator of consistent wealth creation.
| Metric | CLNNClene Inc. | NRXPNRx Pharmaceutica… |
|---|---|---|
| YTD ReturnYear-to-date | +28.1% | +16.8% |
| 1-Year ReturnPast 12 months | +189.8% | +55.3% |
| 3-Year ReturnCumulative with dividends | -60.5% | -50.6% |
| 5-Year ReturnCumulative with dividends | -96.0% | -99.1% |
| 10-Year ReturnCumulative with dividends | -96.2% | -96.8% |
| CAGR (3Y)Annualised 3-year return | -26.6% | -21.0% |
CLNN leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
NRXP leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
NRXP is the less volatile stock with a 1.91 beta — it tends to amplify market swings less than CLNN's 1.97 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NRXP currently trades 79.7% from its 52-week high vs CLNN's 54.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CLNNClene Inc. | NRXPNRx Pharmaceutica… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.97x | 1.91x |
| 52-Week HighHighest price in past year | $13.50 | $3.84 |
| 52-Week LowLowest price in past year | $2.28 | $1.62 |
| % of 52W HighCurrent price vs 52-week peak | +54.7% | +79.7% |
| RSI (14)Momentum oscillator 0–100 | 58.3 | 64.7 |
| Avg Volume (50D)Average daily shares traded | 558K | 913K |
NRXP leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | CLNNClene Inc. | NRXPNRx Pharmaceutica… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CLNN leads in 2 of 6 categories (Income & Cash Flow, Total Returns). NRXP leads in 2 (Profitability & Efficiency, Risk & Volatility). 1 tied.
Best OverallClene Inc. (CLNN)Leads 2 of 6 categories
Loading custom metrics...
CLNN vs NRXP: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — CLNN or NRXP?
Over the past 5 years, Clene Inc.
(CLNN) delivered a total return of -96. 0%, compared to -99. 1% for NRx Pharmaceuticals, Inc. (NRXP). Over 10 years, the gap is even starker: CLNN returned -96. 2% versus NRXP's -96. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — CLNN or NRXP?
By beta (market sensitivity over 5 years), NRx Pharmaceuticals, Inc.
(NRXP) is the lower-risk stock at 1. 91β versus Clene Inc. 's 1. 97β — meaning CLNN is approximately 3% more volatile than NRXP relative to the S&P 500.
03Which is growing faster — CLNN or NRXP?
On earnings-per-share growth, the picture is similar: Clene Inc.
grew EPS 53. 3% year-over-year, compared to 43. 9% for NRx Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — CLNN or NRXP?
NRx Pharmaceuticals, Inc.
(NRXP) is the more profitable company, earning -23. 4% net margin versus -130. 9% for Clene Inc. — meaning it keeps -23. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NRXP leads at -1324. 4% versus -115. 4% for CLNN. At the gross margin level — before operating expenses — CLNN leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — CLNN or NRXP?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is CLNN or NRXP better for a retirement portfolio?
For long-horizon retirement investors, NRx Pharmaceuticals, Inc.
(NRXP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Clene Inc. (CLNN) carries a higher beta of 1. 97 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NRXP: -96. 8%, CLNN: -96. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between CLNN and NRXP?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.